Beyond “Psychotropic”: Repurposing Psychiatric Drugs for COVID-19, Alzheimer’s Disease, and Cancer

References (87)

1. Leon AC. Evolution of psychopharmacology trial design and analysis: six decades in the making. J Clin Psychiatry. 2011;72(3):331–340. PubMed CrossRef
2. Subramanian S, Haroutounian S, Palanca BJA, et al. Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. J Neurol Sci. 2022;434:120152. PubMed CrossRef
3. Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37(1):109–122. PubMed CrossRef
4. Lester HA, Miwa JM, Srinivasan R. Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects. Biol Psychiatry. 2012;72(11):907–915. PubMed CrossRef
5. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos. 2007;35(8):1325–1332. PubMed CrossRef
6. Qureshi Z, Ali MN, Khalid M. An Insight into potential pharmacotherapeutic agents for painful diabetic neuropathy. J Diabetes Res. 2022;2022:9989272. PubMed CrossRef
7. Welsch P, Üçeyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. PubMed CrossRef
8. Banzi R, Cusi C, Randazzo C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015;4(4):CD002919. PubMed CrossRef
9. d’Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache. 1999;39(10):716–719. PubMed CrossRef
10. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174(7):1058–1066. PubMed CrossRef
11. Waldinger MD, Hengeveld MW, Zwinderman AH, et al. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998;18(4):274–281. PubMed CrossRef
12. Calkins H. Pharmacologic approaches to therapy for vasovagal syncope. Am J Cardiol. 1999;84(8):20–25. PubMed CrossRef
13. Nykamp MJ, Zorumski CF, Reiersen AM, et al. Opportunities for drug repurposing of serotonin reuptake inhibitors: potential uses in inflammation, infection, cancer, neuroprotection, and alzheimer’s disease prevention. Pharmacopsychiatry. 2022;55(1):24–29. PubMed CrossRef
14. Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. PubMed CrossRef
15. Nicol GE, Karp JF, Reiersen AM, et al. “What were you before the war?” repurposing psychiatry during the COVID-19 pandemic. J Clin Psychiatry. 2020;81(3):20com13373. PubMed CrossRef
16. Rosen DA, Seki SM, Fernández-Castañeda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. PubMed CrossRef
17. Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117–119. PubMed CrossRef
18. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688. PubMed CrossRef
19. Fritz BA, Hoertel N, Lenze EJ, et al. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12(1):341. PubMed CrossRef
20. Hoertel N, Sánchez-Rico M, Kornhuber J, et al; On Behalf Of Ap-Hp/Université Paris Cité/Inserm Covid-Research Collaboration Ap-Hp Covid Cdr Initiative And Entrepôt de Données de Santé Ap-Hp Consortium. Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA Model against COVID-19. J Clin Med. 2022;11(19):5882. PubMed CrossRef
21. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–2300. PubMed CrossRef
22. Rodebaugh TL, Frumkin MR, Reiersen AM, et al. Acute symptoms of mild to moderate COVID-19 are highly heterogeneous across individuals and over time. Open Forum Infect Dis. 2021;8(3):b090. PubMed CrossRef
23. Reis G, Silva EASM, Silva DCM, et al; TOGETHER Investigators. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med. 2022;386(18):1721–1731. PubMed CrossRef
24. Lee TC, Vigod S, Bortolussi-Courval É, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e226269. PubMed CrossRef
25. Bramante CT, Huling JD, Tignanelli CJ, et al; COVID-OUT Trial Team. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599–610. PubMed CrossRef
26. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of COVID-19. Open Forum Infect Dis. 2021;8(2):b050. PubMed CrossRef
27. Calusic M, Marcec R, Luksa L, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2022;88(5):2065–2073. PubMed CrossRef
28. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330–1341. PubMed CrossRef
29. Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141–152. PubMed CrossRef
30. Zimniak M, Kirschner L, Hilpert H, et al. The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11(1):5890. PubMed CrossRef
31. Carpinteiro A, Edwards MJ, Hoffmann M, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1(8):100142. PubMed CrossRef
32. Hoertel N, Sánchez-Rico M, Gulbins E, et al; AP-HP / Université de Paris / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, “Entrepôt de Données de Santé” AP-HP Consortium. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for Severe COVID-19: an observational multicenter study. Clin Pharmacol Ther. 2021;110(6):1498–1511. PubMed CrossRef
33. Hoertel N, Sánchez-Rico M, Vernet R, et al; AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26(9):5199–5212. PubMed CrossRef
34. Clelland CL, Ramiah K, Steinberg L, et al. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8(1):e6. PubMed CrossRef
35. Oskotsky T, Maric I, Tang A, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4(11):e2133090. PubMed CrossRef
36. Németh ZK, Szûcs A, Vitrai J, et al. Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study. Ideggyogy Sz. 2021;74(11–12):389–396. PubMed CrossRef
37. Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27(9):3562. PubMed CrossRef
38. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. PubMed CrossRef
39. Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2022;4(1):fcab297. PubMed CrossRef
40. Law JC, Girard M, Chao GYC, et al. Persistence of T cell and antibody responses to SARS-CoV-2 up to 9 months after symptom onset. J Immunol. 2022;208(2):429–443. PubMed CrossRef
41. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. PubMed CrossRef
42. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332. PubMed CrossRef
43. Yamada S, Asakura H. Coagulopathy and fibrinolytic pathophysiology in COVID-19 and SARS-CoV-2 vaccination. Int J Mol Sci. 2022;23(6):3338. PubMed CrossRef
44. Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021;78(6):682–683. PubMed CrossRef
45. Mazza MG, Zanardi R, Palladini M, et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2022;54:1–6. PubMed CrossRef
46. Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020;17(7):879–891. PubMed CrossRef
47. Ridenour TA, Wittenborn AK, Raiff BR, et al. Illustrating idiographic methods for translation research: moderation effects, natural clinical experiments, and complex treatment-by-subgroup interactions. Transl Behav Med. 2016;6(1):125–134. PubMed CrossRef
48. Reitz KM, Seymour CW, Vates J, et al. Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients. BMJ Open. 2020;10(9):e037690. PubMed CrossRef
49. Lenze EJ, Nicol GE, Barbour DL, et al. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. J Psychiatry Neurosci. 2021;46(1):E97–E110. PubMed CrossRef
50. Sachs RE, Ginsburg PB, Goldman DP. Encouraging new uses for old drugs. JAMA. 2017;318(24):2421–2422. PubMed CrossRef
51. Sydes MR, Barbachano Y, Bowman L, et al; Data Enabled Trials Group Workshop Group members. Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open. 2021;11(6):e043906. PubMed CrossRef
52. McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191. PubMed CrossRef
53. Ambati M, Apicella I, Wang SB, et al. Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration. Proc Natl Acad Sci U S A. 2021;118(41):e2102975118. PubMed CrossRef
54. de Oliveira P, Cella C, Locker N, et al. Improved sleep, memory, and cellular pathological features of tauopathy, including the NLRP3 inflammasome, after chronic administration of trazodone in rTg4510 Mice. J Neurosci. 2022;42(16):3494–3509. PubMed CrossRef
55. Halliday M, Radford H, Zents KAM, et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain. 2017;140(6):1768–1783. PubMed CrossRef
56. Jiang LX, Huang GD, Su F, et al. Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Psychopharmacology (Berl). 2020;237(4):1233–1243. PubMed CrossRef
57. Bogár F, Fülöp L, Penke B. Novel therapeutic target for prevention of neurodegenerative diseases: modulation of neuroinflammation with Sig-1R ligands. Biomolecules. 2022;12(3):363. PubMed CrossRef
58. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des. 2012;18(7):875–883. PubMed CrossRef
59. Izumi Y, Reiersen AM, Lenze EJ, et al. SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids. Transl Psychiatry. 2023;13(1):39. PubMed CrossRef
60. Cirrito JR, Wallace CE, Yan P, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95(19):e2666–e2674. PubMed CrossRef
61. Lin A, Giuliano CJ, Palladino A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11(509):eaaw8412. PubMed CrossRef
62. Varalda M, Antona A, Bettio V, et al. Psychotropic drugs show anticancer activity by disrupting mitochondrial and lysosomal function. Front Oncol. 2020;10:562196. PubMed CrossRef
63. Song Y, Yang X, Yu B. Repurposing antidepressants for anticancer drug discovery. Drug Discov Today. 2022;27(7):1924–1935. PubMed CrossRef
64. Dai XJ, Liu Y, Xiong XP, et al. Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective. J Med Chem. 2020;63(23):14197–14215. PubMed CrossRef
65. Vlachos N, Lampros M, Voulgaris S, et al. Repurposing antipsychotics for cancer treatment. Biomedicines. 2021;9(12):1785. PubMed CrossRef
66. Papadopoulos F, Isihou R, Alexiou GA, et al. Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. Biomedicines. 2020;8(12):595. PubMed CrossRef
67. Pareek S, Huang Y, Nath A, et al. The success story of drug repurposing in breast cancer. In: To KKW, Cho WCS, eds. Drug Repurposing in Cancer Therapy, Chapter 6. Academic Press; 2020:173–190.
68. Zhelev Z, Ohba H, Bakalova R, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Cancer Chemother Pharmacol. 2004;53(3):267–275. PubMed CrossRef
69. Rahman T, Patrick C, Ma C, et al. Prolactin and estrogen levels in postmenopausal women receiving aripiprazole augmentation treatment for depression. J Clin Psychopharmacol. 2021;41(1):31–35. PubMed CrossRef
70. Barrett AJ. Clinical experience with lithium in aplastic anemia and congenital neutropenia. Adv Exp Med Biol. 1980;127:305–320. PubMed CrossRef
71. Chan HS, Freedman MH, Saunders EF. Stimulation of granulopoiesis in vitro and in vivo using lithium in children with chronic neutropenia. Adv Exp Med Biol. 1980;127:293–304. PubMed CrossRef
72. Kum JJ, Khan ZA. Mechanisms of propranolol action in infantile hemangioma. Dermatoendocrinol. 2015;6(1):e979699. PubMed CrossRef
73. Lamy S, Lachambre MP, Lord-Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010;53(5-6):200–208. PubMed CrossRef
74. Chang PY, Huang WY, Lin CL, et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltimore). 2015;94(27):e1097. PubMed CrossRef
75. Archer M, Dogra N, Dovey Z, et al. Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. Cell Commun Signal. 2021;19(1):78. PubMed CrossRef
76. Lu H, Liu X, Guo F, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. OncoTargets Ther. 2015;8:985–990. PubMed CrossRef
77. Pantziarka P, Bouche G, Sukhatme V, et al. Repurposing drugs in oncology (ReDO)-propranolol as an anti-cancer agent. Ecancermedicalscience. 2016;10:680. PubMed CrossRef
78. Dalwadi DA, Kim S, Schetz JA. Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. Neurochem Int. 2017;105:21–31. PubMed CrossRef
79. Patergnani S, Bonora M, Ingusci S, et al. Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis. Proc Natl Acad Sci U S A. 2021;118(24):e2020078118. PubMed CrossRef
80. Nakagawa C, Yokoyama S, Hosomi K, et al. Repurposing haloperidol for the treatment of rheumatoid arthritis: an integrative approach using data mining techniques. Ther Adv Musculoskelet Dis. 2021;13:X211047057. PubMed CrossRef
81. Landén M, Larsson H, Lichtenstein P, et al. Respiratory infections during lithium and valproate medication: a within-individual prospective study of 50,000 patients with bipolar disorder. Int J Bipolar Disord. 2021;9(1):4. PubMed CrossRef
82. Singh J, Lanzarini E, Santosh P. Organic features of autonomic dysregulation in paediatric brain injury—clinical and research implications for the management of patients with Rett syndrome. Neurosci Biobehav Rev. 2020;118:809–827. PubMed CrossRef
83. Pham T-H, Qiu Y, Zeng J, et al. A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing. Nat Mach Intell. 2021;3(3):247–257. PubMed CrossRef
84. Austin CP. Repurposing Challenges: Conceptualization of a Research Agenda. Global Forum: Driving Insights to Action. National Center for Advancing Translational Sciences; National Institutes of Health website. https://globalforum.diaglobal.org/issue/june-2020/repurposing-challenges-conceptualization-of-a-research-agenda/. 2020. Accessed February 23, 2023.  
85. Sahragardjoonegani B, Beall RF, Kesselheim AS, et al. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. J Pharm Policy Pract. 2021;14(1):3. PubMed CrossRef
86. Gebara MA, Lipsey KL, Karp JF, et al. Cause or effect? selective serotonin reuptake inhibitors and falls in older adults: a systematic review. Am J Geriatr Psychiatry. 2015;23(10):1016–1028. PubMed CrossRef
87. Gleason CE, Dowling NM, Friedman E, et al. Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy? Menopause. 2012;19(5):524–533. PubMed CrossRef